Literature DB >> 28002707

Primary Sclerosing Cholangitis.

Konstantinos N Lazaridis, Nicholas F LaRusso.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 28002707     DOI： 10.1056/NEJMc1613273

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  29 in total

Review 1.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

2.  Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study.

Authors:  Yong Eun Park; Jae Hee Cheon; Jae Jun Park; Yoon Jae Kim; Chang Hwan Choi; Yehyun Park; Soo Jung Park; Tae Il Kim; Won Ho Kim
Journal:  Int J Colorectal Dis       Date:  2018-07-09       Impact factor: 2.571

3.  Proteasomal Degradation of Enhancer of Zeste Homologue 2 in Cholangiocytes Promotes Biliary Fibrosis.

Authors:  Nidhi Jalan-Sakrikar; Thiago M De Assuncao; Guang Shi; Sayed Obaidullah Aseem; Cheng Chi; Vijay H Shah; Robert C Huebert
Journal:  Hepatology       Date:  2019-06-22       Impact factor: 17.425

4.  The Secretin/Secretin Receptor Axis Modulates Ductular Reaction and Liver Fibrosis through Changes in Transforming Growth Factor-β1-Mediated Biliary Senescence.

Authors:  Nan Wu; Fanyin Meng; Tianhao Zhou; Julie Venter; Thao K Giang; Konstantina Kyritsi; Chaodong Wu; Domenico Alvaro; Paolo Onori; Romina Mancinelli; Eugenio Gaudio; Heather Francis; Gianfranco Alpini; Shannon Glaser; Antonio Franchitto
Journal:  Am J Pathol       Date:  2018-07-21       Impact factor: 4.307

5.  Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Deficiency Promotes the Ductular Reaction, Macrophage Accumulation, and Hepatic Fibrosis in the Abcb4-/- Mouse.

Authors:  Anuradha Krishnan; Tomohiro Katsumi; Maria E Guicciardi; Adiba I Azad; Nazli B Ozturk; Christy E Trussoni; Gregory J Gores
Journal:  Am J Pathol       Date:  2020-03-30       Impact factor: 4.307

6.  Unique Phenotypic Characteristics and Clinical Course in Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis: A Multicenter US Experience.

Authors:  Ming-Hsi Wang; Omar Y Mousa; Jessica J Friton; Laura E Raffals; Jonathan A Leighton; Shabana F Pasha; Michael F Picco; Kelly C Cushing; Kelly Monroe; Billy D Nix; Rodney D Newberry; William A Faubion
Journal:  Inflamm Bowel Dis       Date:  2020-04-11       Impact factor: 5.325

7.  Wnt/β-Catenin Signaling Plays a Protective Role in the Mdr2 Knockout Murine Model of Cholestatic Liver Disease.

Authors:  Tirthadipa Pradhan-Sundd; Karis Kosar; Harvinder Saggi; Rong Zhang; Ravi Vats; Pamela Cornuet; Sydney Green; Sucha Singh; Gang Zeng; Prithu Sundd; Kari Nejak-Bowen
Journal:  Hepatology       Date:  2019-12-31       Impact factor: 17.425

Review 8.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

9.  Bile Acid Profiles in Primary Sclerosing Cholangitis and Their Ability to Predict Hepatic Decompensation.

Authors:  Omar Y Mousa; Brian D Juran; Bryan M McCauley; Mette N Vesterhus; Trine Folseraas; Coleman T Turgeon; Ahmad H Ali; Erik M Schlicht; Elizabeth J Atkinson; Chang Hu; Denise Harnois; Elizabeth J Carey; Andrea A Gossard; Devin Oglesbee; John E Eaton; Nicholas F LaRusso; Gregory J Gores; Tom H Karlsen; Konstantinos N Lazaridis
Journal:  Hepatology       Date:  2021-06-15       Impact factor: 17.425

10.  Immunotherapy-based targeting of MSLN+ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis.

Authors:  Takahiro Nishio; Yukinori Koyama; Xiao Liu; Sara B Rosenthal; Gen Yamamoto; Hiroaki Fuji; Jacopo Baglieri; Na Li; Laura N Brenner; Keiko Iwaisako; Kojiro Taura; James S Hagood; Nicholas F LaRusso; Tapan K Bera; Ira Pastan; David A Brenner; Tatiana Kisseleva
Journal:  Proc Natl Acad Sci U S A       Date:  2021-07-20       Impact factor: 12.779
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.